Monthly Berobenatide Injections for Sleep Apnea and Excess Weight in Breathing Machine Users
Tests berobenatide injections against placebo in adults with sleep apnea and excess weight.
Plain-language title generated from the registry record
Registry title: A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)
Key facts
- Where
- Bradenton, Cullman, Dallas, Little Rock, Maplewood, Riverside, Southfield, and Tomball, United StatesSee the 8 sites
- Phase
- Phase 3
Where in United States
- DM Clinical ResearchBradenton, United StatesTaking people
- Cullman Clinical TrialsCullman, United StatesTaking people
- Velocity Clinical Research, DallasDallas, United StatesTaking people
- Preferred Research Partners, IncLittle Rock, United StatesTaking people
- Headlands Research-Twin CitiesMaplewood, United StatesTaking people
- Probe Clinical Research CorporationRiverside, United StatesTaking people
- Revive Research Institute, IncSouthfield, United StatesNot yet recruiting
- DM Clinical ResearchTomball, United StatesNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT07823608
- Record updated
- 5 November 2026
- Original description
This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if berobenatide can help adults with breathing problems during sleep (obstructive sleep apnea [OSA]) and overweight or obesity who use a breathing machine (positive airway pressure [PAP] machine).Read full original descriptionShow less
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH OBSTRUCTIVE SLEEP APNEA AND OVERWEIGHT OR OBESITY RECEIVING POSITIVE AIRWAY PRESSURE THERAPY (VESPER-OSA 1)
This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if berobenatide can help adults with breathing problems during sleep (obstructive sleep apnea [OSA]) and overweight or obesity who use a breathing machine (positive airway pressure [PAP] machine).
People may be able to take part if they are adults with moderate to severe OSA, have overweight or obesity, and have been using PAP therapy before joining the study. Participants will be assigned by chance to receive either berobenatide or a placebo (a treatment that looks like the study medicine but contains no active medicine). The study treatment will be given as an injection under the skin approximately once a month. Participants will receive study treatment at study sites and may administer some doses at home after receiving training.
During the study, participants will attend study visits, undergo sleep studies, complete questionnaires, and have health assessments performed. Researchers will compare the effects of berobenatide and placebo on sleep apnea, body weight, and other health measures.
Inclusion: Adults aged 18 years or older; Body mass index (BMI) ≥27 kg/m² at screening; Previously diagnosed with moderate to severe obstructive sleep apnea (OSA); Ongoing positive airway pressure (PAP) therapy for obstructive sleep apnea that is expected to continue during the study.
Exclusion: Self-reported body weight change of more than 5% within 90 days prior to screening; Diagnosis of any type of diabetes (resolved gestational diabetes is permitted); History of acute or chronic pancreatitis; Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2) Sleep-disordered breathing conditions other than obstructive sleep apnea that could interfere with study assessments or interpretation of results (eg, central sleep apnea, mixed sleep apnea, Cheyne-Stokes respiration, obesity hypoventilation syndrome, or significant craniofacial abnormalities).